Read on Twitter
Disgraceful for anyone to politicise such a critical issue.
Sh @ShashiTharoor, Sh @yadavakhilesh & Sh @Jairam_Ramesh don't try to discredit well laid out science-backed protocols followed for approving #COVID19vaccines
Wake up & realise you are only discrediting yourselves !
Sh @ShashiTharoor, Sh @yadavakhilesh & Sh @Jairam_Ramesh don't try to discredit well laid out science-backed protocols followed for approving #COVID19vaccines
Wake up & realise you are only discrediting yourselves !
Vaccines approved globally based on gene encoding spike proteins have protective efficacy of over 90%
However, COVAXIN based on whole inactivated virus has other antigenic epitopes in addition to spike protein
So,it’s likely to have similar protective efficacy reported for others
However, COVAXIN based on whole inactivated virus has other antigenic epitopes in addition to spike protein
So,it’s likely to have similar protective efficacy reported for others
COVAXIN is more likely to work against newer variants like N501Y Variant (UK variant) & any other that may arise due to antigenic drift as it contains immunogens (epitopes) from other genes in addition to those from Spike protein
Inactivated virus from NIV also had D614G mutation
Inactivated virus from NIV also had D614G mutation
The data from COVAXIN Phase I & II clinical trials reveals that it not only produces neutralizing antibodies in all participants but also sensitises CD4 T lymphocytes that imparts durable immune response
@BharatBiotech @PMOIndia @ICMRDELHI @icmr_niv @MoHFW_INDIA @DBTIndia
@BharatBiotech @PMOIndia @ICMRDELHI @icmr_niv @MoHFW_INDIA @DBTIndia
Our experience with inactivated vaccines not having serious adverse events was also observed in Phase II done among 380 study participants in BBV152 trial in 21280 Person days follow up.
No serious adverse events seen. Only 7% persons receiving 6 microgram dose had mild symptoms.
No serious adverse events seen. Only 7% persons receiving 6 microgram dose had mild symptoms.
There were no seroconversions in those who were provided vaccines in Phase II as well as Phase I of COVAXIN clinical trials.
@ICMRDELHI @MoHFW_INDIA @icmr_niv @DBTIndia @BharatBiotech
@ICMRDELHI @MoHFW_INDIA @icmr_niv @DBTIndia @BharatBiotech
